These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22901442)

  • 1. Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
    Qi WX; Tang LN; He AN; Shen Z; Yao Y
    Breast; 2013 Jun; 22(3):314-9. PubMed ID: 22901442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
    Pallis AG; Boukovinas I; Ardavanis A; Varthalitis I; Malamos N; Georgoulias V; Mavroudis D
    Ann Oncol; 2012 May; 23(5):1164-1169. PubMed ID: 21937705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
    Park JS; Jeung HC; Rha SY; Ahn JB; Kang B; Chon HJ; Hong MH; Lim S; Yang WI; Nam CM; Chung HC
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):799-808. PubMed ID: 25107569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.
    Yu YF; Wang Y; Fu TP; Chen K; Liu JQ; Yao HR
    Breast Cancer Res Treat; 2018 Apr; 168(2):337-348. PubMed ID: 29188398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
    Karachaliou N; Ziras N; Syrigos K; Tryfonidis K; Papadimitraki E; Kontopodis E; Bozionelou V; Kalykaki A; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):169-76. PubMed ID: 22669571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Capecitabine Alone or in Combination in Advanced Metastatic Breast Cancer Patients Previously Treated with Anthracycline and Taxane: A Systematic Review and Meta-Analysis.
    Alsaloumi L; Shawagfeh S; Abdi A; Basgut B
    Oncol Res Treat; 2020; 43(12):694-702. PubMed ID: 32950984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
    Qi WX; Shen Z; Yao Y
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):99-106. PubMed ID: 21607554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Qi WX; Tang LN; He AN; Shen Z; Lin F; Yao Y
    Lung; 2012 Oct; 190(5):477-85. PubMed ID: 22711060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.
    Jiang Y; Yin W; Zhou L; Yan T; Zhou Q; Du Y; Shen Z; Shao Z; Lu J
    PLoS One; 2012; 7(3):e32474. PubMed ID: 22396769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of taxane and anthracycline combination regimens in the management of advanced breast cancer: a meta-analysis of randomized trials.
    Zheng R; Han S; Duan C; Chen K; You Z; Jia J; Lin S; Liang L; Liu A; Long H; Wang S
    Medicine (Baltimore); 2015 May; 94(17):e803. PubMed ID: 25929935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane.
    Martin M; Campone M; Bondarenko I; Sakaeva D; Krishnamurthy S; Roman L; Lebedeva L; Vedovato JC; Aapro M
    Ann Oncol; 2018 May; 29(5):1195-1202. PubMed ID: 29447329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors.
    Gilabert M; Bertucci F; Esterni B; Madroszyk A; Tarpin C; Jacquemier J; Extra JM; Viens P; Gonçalves A
    Anticancer Res; 2011 Mar; 31(3):1079-86. PubMed ID: 21498742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
    Li T; Guo M; Gradishar WJ; Sparano JA; Perez EA; Wang M; Sledge GW
    Breast Cancer Res Treat; 2012 Jul; 134(1):345-52. PubMed ID: 22547107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of combination therapy versus single-agent therapy in anthracycline- and taxane-pretreated metastatic breast cancer: results from nine randomized Phase III trials.
    Xu L; Wu X; Hu C; Zhang Z; Zhang L; Liang S; Xu Y; Zhang F
    Onco Targets Ther; 2016; 9():4061-74. PubMed ID: 27445497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemcitabine plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
    Dong N; Wu Y; Song C; Wang M; Jiao Y; Zhang S
    J BUON; 2020; 25(3):1348-1353. PubMed ID: 32862575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01).
    Park IH; Im SA; Jung KH; Sohn JH; Park YH; Lee KS; Sim SH; Park KH; Kim JH; Nam BH; Kim HJ; Kim TY; Lee KH; Kim SB; Ahn JH; Lee S; Ro J
    Cancer Res Treat; 2019 Jan; 51(1):43-52. PubMed ID: 29458237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.
    Hortobagyi GN; Gomez HL; Li RK; Chung HC; Fein LE; Chan VF; Jassem J; Lerzo GL; Pivot XB; Hurtado de Mendoza F; Xu B; Vahdat LT; Peck RA; Mukhopadhyay P; Roché HH
    Breast Cancer Res Treat; 2010 Jul; 122(2):409-18. PubMed ID: 20454927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.